Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Cash (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Change in Cash for 13 consecutive years, with -$3.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 97.98% year-over-year to -$3.6 million, compared with a TTM value of $12.9 million through Dec 2025, up 207.74%, and an annual FY2025 reading of $12.9 million, up 207.74% over the prior year.
  • Change in Cash was -$3.6 million for Q4 2025 at Agios Pharmaceuticals, down from $11.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.8 billion in Q1 2021 and bottomed at -$918.9 million in Q2 2021.
  • Average Change in Cash over 5 years is -$1.9 million, with a median of -$836500.0 recorded in 2025.
  • Peak annual rise in Change in Cash hit 21470.56% in 2021, while the deepest fall reached 972.85% in 2021.
  • Year by year, Change in Cash stood at -$197.1 million in 2021, then soared by 108.53% to $16.8 million in 2022, then soared by 42.01% to $23.9 million in 2023, then plummeted by 843.48% to -$177.5 million in 2024, then surged by 97.98% to -$3.6 million in 2025.
  • Business Quant data shows Change in Cash for AGIO at -$3.6 million in Q4 2025, $11.8 million in Q3 2025, and $1.9 million in Q2 2025.